Bank of New York Mellon Corp - TG THERAPEUTICS INC ownership

TG THERAPEUTICS INC's ticker is TGTX and the CUSIP is 88322Q108. A total of 132 filers reported holding TG THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 1.20 and the average weighting 0.1%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of TG THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$4,846,248
-66.9%
579,695
-1.7%
0.00%
-66.7%
Q2 2023$14,646,636
+107.5%
589,639
+25.7%
0.00%
+50.0%
Q1 2023$7,057,265
+20.1%
469,233
-5.5%
0.00%
+100.0%
Q4 2022$5,874,743
+120.1%
496,597
+10.1%
0.00%0.0%
Q3 2022$2,669,000
+57.4%
450,877
+13.1%
0.00%
Q2 2022$1,696,000
-66.5%
398,776
-25.0%
0.00%
-100.0%
Q1 2022$5,059,000
-50.0%
532,054
-0.0%
0.00%
-50.0%
Q4 2021$10,110,000
-46.2%
532,101
-5.8%
0.00%
-50.0%
Q3 2021$18,802,000
-8.9%
564,978
+6.2%
0.00%0.0%
Q2 2021$20,640,000
-16.0%
532,100
+4.3%
0.00%
-20.0%
Q1 2021$24,585,000
-10.5%
510,082
-3.5%
0.01%
-16.7%
Q4 2020$27,484,000
+120.2%
528,348
+13.3%
0.01%
+100.0%
Q3 2020$12,479,000
+47.0%
466,317
+7.0%
0.00%
+50.0%
Q2 2020$8,490,000
+137.7%
435,818
+20.1%
0.00%
+100.0%
Q1 2020$3,571,000
-0.9%
362,900
+11.8%
0.00%0.0%
Q4 2019$3,602,000
+107.1%
324,590
+4.8%
0.00%
Q3 2019$1,739,000
-35.4%
309,689
-0.4%
0.00%
-100.0%
Q2 2019$2,690,000
+18.9%
311,004
+10.5%
0.00%0.0%
Q1 2019$2,262,000
+98.2%
281,377
+1.1%
0.00%
Q4 2018$1,141,000
-29.0%
278,294
-3.0%
0.00%
Q3 2018$1,606,000
-55.8%
286,843
+3.8%
0.00%
-100.0%
Q2 2018$3,633,000
+3.4%
276,325
+11.7%
0.00%0.0%
Q1 2018$3,512,000
+74.2%
247,313
+0.6%
0.00%0.0%
Q4 2017$2,016,000
-43.1%
245,856
-17.7%
0.00%0.0%
Q3 2017$3,540,000
+18.5%
298,649
+0.5%
0.00%0.0%
Q2 2017$2,987,000
-5.7%
297,176
+9.3%
0.00%0.0%
Q1 2017$3,168,000
+252.4%
271,879
+40.7%
0.00%
Q4 2016$899,000
-34.1%
193,235
+9.7%
0.00%
Q3 2016$1,364,000
+27.5%
176,168
-0.3%
0.00%
Q2 2016$1,070,000
-22.9%
176,637
+8.4%
0.00%
Q1 2016$1,387,000
-32.6%
162,888
-5.6%
0.00%
-100.0%
Q4 2015$2,059,000
+20.1%
172,579
+1.4%
0.00%0.0%
Q3 2015$1,715,000
-59.5%
170,183
-33.4%
0.00%0.0%
Q2 2015$4,239,000
+22.2%
255,485
+14.0%
0.00%0.0%
Q1 2015$3,468,000
-4.3%
224,052
-2.1%
0.00%0.0%
Q4 2014$3,624,000
+65.0%
228,814
+11.2%
0.00%0.0%
Q3 2014$2,196,000
-2.9%
205,811
-14.5%
0.00%
Q2 2014$2,262,000
+266.6%
240,806
+168.9%
0.00%
Q1 2014$617,000
+103.6%
89,564
+15.5%
0.00%
Q4 2013$303,000
-60.0%
77,551
-48.5%
0.00%
Q3 2013$758,000
+83.1%
150,616
+132.5%
0.00%
Q2 2013$414,00064,7730.00%
Other shareholders
TG THERAPEUTICS INC shareholders Q3 2018
NameSharesValueWeighting ↓
Lion Point Capital, LP 839,128$27,926,0005.24%
RA Capital Management 4,098,332$136,392,0001.89%
KLK CAPITAL MANAGEMENT LLC 45,762$1,523,0001.40%
Antara Capital LP 520,800$17,332,0001.33%
Spotlight Asset Group, Inc. 75,000$2,496,0001.24%
Nicholas Investment Partners, LP 485,838$16,169,0001.18%
MAVERICK CAPITAL LTD 3,296,451$109,706,0001.11%
SECTORAL ASSET MANAGEMENT INC 394,949$13,144,0001.09%
683 Capital Management, LLC 828,271$27,565,0001.08%
ACT CAPITAL MANAGEMENT, LLC 60,000$1,997,0001.04%
View complete list of TG THERAPEUTICS INC shareholders